Amicus Therapeutics Stock Options
FOLD Stock | USD 9.01 0.07 0.77% |
Amicus Therapeutics' latest option contracts expiring on May 16th 2025 are carrying combined implied volatility of 1.52. The Amicus Therapeutics option chain provides detailed quote and price information for the current Amicus Therapeutics option contracts. It shows all of Amicus Therapeutics' listed puts, calls, expiration dates, strike prices, and other pricing information.
Amicus Therapeutics Maximum Pain Price Across 2025-05-16 Option Contracts
Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Amicus Therapeutics close to expiration to expire worthless. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, Amicus Therapeutics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Amicus Therapeutics
Analyzing Amicus Therapeutics' in-the-money options over time can help investors to take a profitable long position in Amicus Therapeutics regardless of its overall volatility. This is especially true when Amicus Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Amicus Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Amicus Therapeutics' stock while costing only a fraction of its price.
Amicus Therapeutics' stock options are financial instruments that give investors the right to buy or sell shares of Amicus Therapeutics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Amicus stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Amicus Therapeutics' stock price goes up or down, the stock options follow.
At present, Amicus Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Common Stock is expected to grow to about 3.1 M, whereas Liabilities And Stockholders Equity is forecasted to decline to about 491.9 M. Amicus Therapeutics In The Money Call Balance
When Amicus Therapeutics' strike price is surpassing the current stock price, the option contract against Amicus Therapeutics stock is said to be in the money. When it comes to buying Amicus Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Amicus Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Amicus Current Options Market Mood
Amicus Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Amicus Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Volume
Unfortunately, most Amicus Therapeutics' options investors are not very successful. Amicus Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Amicus contract
Base on the Rule 16, the options market is currently suggesting that Amicus Therapeutics will have an average daily up or down price movement of about 0.095% per day over the life of the 2025-05-16 option contract. With Amicus Therapeutics trading at USD 9.01, that is roughly USD 0.00856. If you think that the market is fully incorporating Amicus Therapeutics' daily price movement you should consider buying Amicus Therapeutics options at the current volatility level of 1.52%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Amicus |
Purchasing Amicus Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Amicus calls. Remember, the seller must deliver Amicus Therapeutics stock to the call owner when a call is exercised.
Amicus Therapeutics Option Chain
When Amicus Therapeutics' strike price is surpassing the current stock price, the option contract against Amicus Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Amicus Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Amicus. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Amicus. It also shows strike prices and maturity days for a Amicus Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. Open Int | Strike Price | Current Spread | Last Price | |||
Call | FOLD250516C00017000 | 0 | 17.0 | 0.0 - 0.75 | 0.75 | |
Call | FOLD250516C00016000 | 0 | 16.0 | 0.0 - 0.75 | 0.75 | |
Call | FOLD250516C00015000 | 0 | 15.0 | 0.0 - 0.75 | 0.75 | |
Call | FOLD250516C00014000 | 0 | 14.0 | 0.0 - 0.75 | 0.75 | |
Call | FOLD250516C00013000 | 0 | 13.0 | 0.0 - 0.75 | 0.75 | |
Call | FOLD250516C00012000 | 0 | 12.0 | 0.0 - 0.7 | 0.7 | |
Call | FOLD250516C00011000 | 0 | 11.0 | 0.0 - 0.7 | 0.7 | |
Call | FOLD250516C00010000 | 0 | 10.0 | 0.0 - 2.75 | 2.75 | |
Call | FOLD250516C00009000 | 0 | 9.0 | 0.2 - 4.9 | 0.2 | |
Call | FOLD250516C00008000 | 0 | 8.0 | 1.1 - 5.0 | 1.1 | In |
Put | FOLD250516P00017000 | 0 | 17.0 | 5.5 - 9.8 | 5.5 | In |
Put | FOLD250516P00016000 | 0 | 16.0 | 4.5 - 9.1 | 4.5 | In |
Put | FOLD250516P00015000 | 0 | 15.0 | 3.5 - 8.3 | 3.5 | In |
Put | FOLD250516P00014000 | 0 | 14.0 | 2.5 - 7.3 | 2.5 | In |
Put | FOLD250516P00013000 | 0 | 13.0 | 3.2 - 4.7 | 3.2 | In |
Put | FOLD250516P00012000 | 0 | 12.0 | 2.35 - 4.5 | 2.35 | In |
Put | FOLD250516P00011000 | 0 | 11.0 | 0.6 - 4.4 | 0.6 | In |
Put | FOLD250516P00010000 | 0 | 10.0 | 0.85 - 4.9 | 0.85 | In |
Put | FOLD250516P00009000 | 0 | 9.0 | 0.1 - 4.9 | 0.1 | |
Put | FOLD250516P00008000 | 0 | 8.0 | 0.1 - 0.75 | 0.1 |
Amicus Therapeutics Market Cap Over Time
Market Cap |
Timeline |
Amicus Total Stockholder Equity
Total Stockholder Equity |
|
Amicus Therapeutics Corporate Management
David Clark | Chief Officer | Profile | |
Patrik Esq | Global Officer | Profile | |
Patrik Florencio | Global VP | Profile | |
Simon Harford | Chief Officer | Profile | |
Ellen Rosenberg | General Counsel and Corporate Secretary | Profile | |
Ellen JD | Chief Secretary | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.18) | Revenue Per Share | Quarterly Revenue Growth 0.301 | Return On Assets | Return On Equity |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.